https://www.banglajol.info/index.php/IJPLS/issue/feedInternational Journal of Pharmaceutical and Life Sciences2014-01-13T02:31:27+00:00Mohammed Raihan Chowdhuryeditor@ijlsbd.comOpen Journal SystemsA Knowledge Searching and Escalation Initiative. Published by Mohammed Raihan Chowdhury. Also available at <a title="IJLSBD" href="http://www.ijlsbd.com/" target="_blank">http://www.ijlsbd.com/</a>.<br /> Full text articles available.https://www.banglajol.info/index.php/IJPLS/article/view/17627A Chronopharmacological Study Related to Doxorubicin Based Bone Marrow Suppression2014-01-13T02:31:27+00:00Vijayalakshmi Subbiahdrsviji2010@gmail.comK Rajendrandrsviji2010@gmail.comM Shanthidrsviji2010@gmail.comR Parameswaridrsviji2010@gmail.com<p>Myelosuppression is the most common toxicity of anti-neoplastic therapy due to inhibition of cell replication in bone marrow. This can be minimized by administering drugs on the basis of circadian time basis. Hence the aim is to study circadian time cycle related bone marrow suppression variation resulting from doxorubicin based cancer chemo therapy regimen. A prospective observational clinical study based on circadian time Cycle was done for a period of six months at a tertiary care hospital. Standard doxorubicin Regimen was given in the dose of 60 mg/m as iv infusion. Each cycle is repeated every 21 Days. Complete hemogram was done on day 0 and day 10 of both day and night cycle. Results were analyzed using students paired t test. It was found that during Night cycle therapy bone marrow suppression was minimal and statistically significant (p<0.001). Chronotherapy is useful in minimizing bone marrow toxicity.</p><p>DOI: <a href="http://dx.doi.org/10.3329/ijpls.v2i5.17627">http://dx.doi.org/10.3329/ijpls.v2i5.17627</a></p> <p>International Journal of Pharmaceutical and Life Sciences, Volume 2(5) Dec 2013: 197-201</p>2014-01-13T00:00:00+00:00Copyright (c) https://www.banglajol.info/index.php/IJPLS/article/view/17628Galactosylated Albumin Nanoparticles Bearing Cimetidine2014-01-13T02:31:27+00:00Kumar Ganesharchana.dhyani89@gmail.comDhyani Archanaarchana.dhyani89@gmail.comKathiyal Preetiarchana.dhyani89@gmail.com<p>The galacotsylated albumin nanoparticles were prepared for the selective delivery of Cimetidine to the asialoglycoprotein receptor (ASGP-R) which is particularly presents on mammalian hepatocytes. The albumin nanoparticles (NPs) were prepared by using desolvation method and efficiently conjugated with galactose. Various parameters such as particle size, % entrapment efficiency and drug loading efficiency, percentage yield, <em>in vitro </em>drug release, were determined. The size of nanoparticles (both plain and galactose coated) was found to be in range of 200-250 nm, and maximum drug payload was found to be 19.08% ± 1.10 .The maximum drug content was found to be 30.80% ± 0.3 and 27.09% ± 0.5 respectively in plain and galactose coated nanoparticles while the maximum entrapment efficiency was found to be 90.68% ± 0.5 and 91.75% ± 0.59 in plain and coated nanoparticles. It was also found that coating of nanoparticles increases the size of nanoparticles. From the in-vitro studies, it was concluded that increase in polymer concentration, decreases the drug releases from the nanoparticles.</p> <p>DOI: <a href="http://dx.doi.org/10.3329/ijpls.v2i5.17628">http://dx.doi.org/10.3329/ijpls.v2i5.17628</a></p> <p>International Journal of Pharmaceutical and Life Sciences, Volume 2(5) Dec 2013: 202-229</p>2014-01-13T00:00:00+00:00Copyright (c)